MA55142A - Amino-triazolopyrimidine et amino-triazolopyrazine substitués antagoniste du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation - Google Patents
Amino-triazolopyrimidine et amino-triazolopyrazine substitués antagoniste du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisationInfo
- Publication number
- MA55142A MA55142A MA055142A MA55142A MA55142A MA 55142 A MA55142 A MA 55142A MA 055142 A MA055142 A MA 055142A MA 55142 A MA55142 A MA 55142A MA 55142 A MA55142 A MA 55142A
- Authority
- MA
- Morocco
- Prior art keywords
- amino
- triazolopyrazine
- triazolopyrimidine
- pharmaceutical compositions
- receptor antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862769843P | 2018-11-20 | 2018-11-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA55142A true MA55142A (fr) | 2022-02-23 |
Family
ID=70774154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA055142A MA55142A (fr) | 2018-11-20 | 2019-11-15 | Amino-triazolopyrimidine et amino-triazolopyrazine substitués antagoniste du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210395255A1 (fr) |
EP (1) | EP3883575A4 (fr) |
JP (1) | JP2022507734A (fr) |
KR (1) | KR20210093964A (fr) |
CN (1) | CN113015530A (fr) |
AU (1) | AU2019383948A1 (fr) |
BR (1) | BR112021009078A8 (fr) |
CA (1) | CA3119774A1 (fr) |
MA (1) | MA55142A (fr) |
MX (1) | MX2021005839A (fr) |
WO (1) | WO2020106558A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020112700A1 (fr) | 2018-11-30 | 2020-06-04 | Merck Sharp & Dohme Corp. | Dérivés amino triazolo quinazoline 9-substitués utiles en tant qu'antagonistes du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation |
JP2022545923A (ja) * | 2019-08-26 | 2022-11-01 | インサイト・コーポレイション | A2a/a2b阻害剤としてのトリアゾロピリミジン |
WO2023201267A1 (fr) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Polythérapie pour le traitement de cancers exprimant trop-2 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU743910B2 (en) * | 1997-03-24 | 2002-02-07 | Kyowa Hakko Kirin Co., Ltd. | {1,2,4}triazolo{1,5-c}pyrimidine derivatives |
JPWO2003028732A1 (ja) * | 2001-09-28 | 2005-01-13 | 協和醗酵工業株式会社 | 受容体拮抗剤 |
PE20030739A1 (es) * | 2001-11-30 | 2003-08-28 | Schering Corp | Antagonistas del receptor de adenosina a2a |
WO2003068776A1 (fr) * | 2002-02-15 | 2003-08-21 | Kyowa Hakko Kogyo Co., Ltd. | Derives de (1, 2, 4) triazolo (1,5-c) pyrimidine |
DK2206517T3 (da) | 2002-07-03 | 2023-11-06 | Ono Pharmaceutical Co | Immunpotentierende sammensætninger omfattende af anti-PD-L1-antistoffer |
US20060058320A1 (en) * | 2002-09-24 | 2006-03-16 | Kyowa Hakko Kogyo Co., Ltd. | [1,2,4] Triazolo[1,5-c]pyrimidine derivatives |
EP1576014B1 (fr) | 2002-12-23 | 2011-06-29 | Wyeth LLC | Anticorps anti pd-1 et leurs utilisations |
EP2270051B1 (fr) | 2003-01-23 | 2019-05-15 | Ono Pharmaceutical Co., Ltd. | Anticorps spécifiques de PD-1 et CD3 humains |
WO2004092177A1 (fr) * | 2003-04-09 | 2004-10-28 | Biogen Idec Ma Inc. | Triazolopyrazines et procedes de preparation et d'utilisation ce celles-ci |
CA3151350A1 (fr) | 2005-05-09 | 2006-11-16 | E. R. Squibb & Sons, L.L.C. | Anticorps monoclonaux humains pour mort programmee 1 (mp-1) et procedes pour traiter le cancer en utilisant des anticorps anti-mp-1 seuls ou associes a d'autres immunotherapies |
EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
SI2170959T1 (sl) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Protitelesa proti receptorjem pd-1 za humano programirano smrt |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
DE102008023801A1 (de) * | 2008-05-15 | 2009-11-19 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine |
GB0906579D0 (en) * | 2009-04-16 | 2009-05-20 | Vernalis R&D Ltd | Pharmaceuticals, compositions and methods of making and using the same |
JP2012510429A (ja) | 2008-08-25 | 2012-05-10 | アンプリミューン、インコーポレーテッド | Pd−1アンタゴニストおよびその使用方法 |
KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-pd-1, pd-l1, 및 pd-l2 항체 및 그의 용도 |
DK4209510T5 (da) | 2008-12-09 | 2024-07-22 | Hoffmann La Roche | Anti-pd-l1-antistoffer og deres anvendelse til at fremme t-cellefunktion |
EP2504028A4 (fr) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | Inhibition simultanée de pd-l1/pd-l2 |
JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック, インコーポレイテッド | Pd−1軸結合アンタゴニストとmek阻害剤を使用する癌の治療方法 |
WO2017223414A1 (fr) * | 2016-06-24 | 2017-12-28 | Incyte Corporation | Composants hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-y |
PL3611174T3 (pl) | 2017-04-07 | 2022-08-08 | Medshine Discovery Inc. | Pochodne [1,2,4]triazolo[1,5-c]pirymidyny jako inhibitor receptora a2a |
CN109535161B (zh) | 2017-09-22 | 2021-09-03 | 江苏恒瑞医药股份有限公司 | 三唑并嘧啶类衍生物、其制备方法及其在医药上的应用 |
CR20200441A (es) | 2018-02-27 | 2021-03-15 | Incyte Corp | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b |
-
2019
- 2019-11-15 US US17/292,511 patent/US20210395255A1/en active Pending
- 2019-11-15 EP EP19886307.8A patent/EP3883575A4/fr active Pending
- 2019-11-15 JP JP2021527186A patent/JP2022507734A/ja active Pending
- 2019-11-15 KR KR1020217018498A patent/KR20210093964A/ko unknown
- 2019-11-15 CA CA3119774A patent/CA3119774A1/fr active Pending
- 2019-11-15 MA MA055142A patent/MA55142A/fr unknown
- 2019-11-15 WO PCT/US2019/061622 patent/WO2020106558A1/fr unknown
- 2019-11-15 BR BR112021009078A patent/BR112021009078A8/pt not_active Application Discontinuation
- 2019-11-15 CN CN201980076511.2A patent/CN113015530A/zh active Pending
- 2019-11-15 AU AU2019383948A patent/AU2019383948A1/en not_active Abandoned
- 2019-11-15 MX MX2021005839A patent/MX2021005839A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP3883575A1 (fr) | 2021-09-29 |
CA3119774A1 (fr) | 2020-05-28 |
CN113015530A (zh) | 2021-06-22 |
MX2021005839A (es) | 2021-07-15 |
BR112021009078A2 (pt) | 2021-08-10 |
BR112021009078A8 (pt) | 2023-02-07 |
KR20210093964A (ko) | 2021-07-28 |
US20210395255A1 (en) | 2021-12-23 |
JP2022507734A (ja) | 2022-01-18 |
EP3883575A4 (fr) | 2022-06-15 |
WO2020106558A1 (fr) | 2020-05-28 |
AU2019383948A1 (en) | 2021-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49753A (fr) | Agents de liaison se liant à pd-l1 et cd137 et leur utilisation | |
IL279015A (en) | Anti-interleukin-17A antibody, its pharmaceutical preparation and its use | |
MA54298A (fr) | Dérivés amino triazolo quinazoline 9-substitués utiles en tant qu'antagonistes du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation | |
MA52245A (fr) | Promédicaments d'antagonistes de c5ar bicycliques fusionnés | |
MA50663A (fr) | Formulations stables d'anticorps anti-récepteur de mort programmée 1 (pd-1) et leur utilisation | |
MA49270A (fr) | Récepteurs de liaison à l'antigène améliorés | |
MA52257A (fr) | Compositions pharmaceutiques comprenant blautia et leur administration orale | |
MA52284A (fr) | Anticorps anti-hla-g et leur utilisation | |
MA55142A (fr) | Amino-triazolopyrimidine et amino-triazolopyrazine substitués antagoniste du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation | |
MA52285A (fr) | Anticorps multispécifiques et leur utilisation | |
MA50175A (fr) | Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés | |
MA54395A (fr) | Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale | |
MA52249A (fr) | Antagonistes de l'intégrine humaine (alpha4) (beta7) | |
IL279152A (en) | Melanocortin subtype-2 receptor antagonists and uses thereof | |
IL277144A (en) | Adenosine receptor antagonists and uses thereof | |
EP3883576A4 (fr) | Composés amino-triazolopyrimidine et amino-triazolopyrazine substitués utilisés en tant qu'antagonistes de récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation | |
MA53218A (fr) | Antagonistes de l'intégrine | |
EP3594221A4 (fr) | Antagoniste du récepteur gpr84 et son utilisation | |
MA52098A (fr) | Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation | |
WO2015116856A3 (fr) | Antagonistes du récepteur x de farnésoïde | |
MA55015A (fr) | Formulations pharmaceutiques | |
MA42527A (fr) | Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation | |
IL276290A (en) | Heteroaryl compounds, their pharmaceutical preparations and their medical use | |
MA49524A (fr) | Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression | |
GB2590189B (en) | Lycorine derivative, and pharmaceutical composition and use thereof |